Cargando…
Cost-effectiveness of colorectal cancer screening in Germany: current endoscopic and fecal testing strategies versus plasma methylated Septin 9 DNA
Background and study aims: Colorectal cancer (CRC) screening strategies in Germany include guaiac-based fecal occult blood testing (gFOBT) starting at age 50 and a switch to colonoscopy at age 55 or continued gFOBT testing, but screening utilization is limited. Blood-based biomarkers, such as methyl...
Autores principales: | Ladabaum, Uri, Alvarez-Osorio, Lourdes, Rösch, Thomas, Brueggenjuergen, Bernd |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
© Georg Thieme Verlag KG
2014
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4440365/ https://www.ncbi.nlm.nih.gov/pubmed/26135268 http://dx.doi.org/10.1055/s-0034-1377182 |
Ejemplares similares
-
Methylated SEPTIN9 plasma test for colorectal cancer detection may be applicable to Lynch syndrome
por: Hitchins, Megan P, et al.
Publicado: (2019) -
Plasma Septin9 versus Fecal Immunochemical Testing for Colorectal Cancer Screening: A Prospective Multicenter Study
por: Johnson, David A., et al.
Publicado: (2014) -
Diagnostic Value of Methylated Septin9 for Colorectal Cancer Detection
por: Xie, Li, et al.
Publicado: (2018) -
Plasma levels of methylated septin 9 are capable of detecting hepatocellular carcinoma and hepatic cirrhosis
por: He, Na, et al.
Publicado: (2020) -
Clinical value of preoperative methylated septin 9 in Chinese colorectal cancer patients
por: Yang, Xue, et al.
Publicado: (2019)